Pharmaceutical giant Eli Lilly plans to construct three manufacturing plants in the US to produce key raw ingredients for its medicines, aiming to reduce dependence on foreign sources. The move has sparked criticism, with some commenting that it is driven by profit motives and tax breaks rather than a genuine interest in domestic job creation.
Source: https://www.washingtonpost.com/business/2025/02/26/eli-lilly-drug-manufacturing-tariffs-domestic